Xilio Therapeutics Shares Surge as CEO and Six Insiders Grab 30,000 Zero‑Cost Options in Coordinated Move
Insider option grants at Xilio signal confidence in its immuno‑oncology pipeline—potential upside for shareholders if upcoming clinical milestones succeed.
3 minutes to read